Recall on metformin
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
Recall on Metformin Due to Nitrosamine Contamination
Introduction to Metformin Recalls
Metformin, a widely used medication for managing type 2 diabetes, has recently been subject to recalls due to contamination concerns. The primary issue involves the detection of N-nitrosodimethylamine (NDMA), a nitrosamine impurity that is potentially genotoxic and carcinogenic. This article synthesizes the findings from various studies and regulatory reports on the recall of metformin products.
Detection of NDMA in Metformin Products
International Regulatory Collaboration
An international regulatory laboratory network has been actively monitoring metformin for nitrosamine impurities. Between November 2019 and July 2020, 1090 samples of metformin, including 875 finished dosage forms (FDFs) and 215 active pharmaceutical ingredient (API) samples, were tested. NDMA was detected in some batches of metformin products, with 17.8% of the FDF samples containing NDMA levels above the acceptable intake (AI) of 96 ng per day. However, 82.2% of the samples met the quality and safety standards for patients.
Specific Batch Recalls
In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) recalled a specific batch of Rosement Pharmaceuticals’ metformin oral solution due to NDMA levels exceeding the acceptable limit. The batch in question, Metformin Hydrochloride 500mg/5ml Oral Solution (batch number 0LL0018), was first distributed in December 2020. The recall was a precautionary measure, and patients were advised to continue taking their medication while seeking advice from healthcare professionals.
Implications and Ongoing Efforts
Patient Safety and Regulatory Actions
The presence of NDMA in metformin products has raised significant concerns due to its potential long-term health risks. Regulatory agencies are collaborating extensively to understand the root causes of nitrosamine formation and to implement corrective actions. These efforts aim to mitigate the presence of NDMA in future batches of metformin, ensuring the safety and efficacy of the medication for patients .
Recommendations for Patients and Healthcare Providers
Patients currently taking metformin are advised to continue their medication but should consult their healthcare providers for guidance. Healthcare professionals are instructed to stop supplying the affected batches and return any remaining stock to the supplier. Continuous monitoring and investigation by regulatory authorities are crucial to prevent future contamination issues.
Conclusion
The recall of metformin due to NDMA contamination highlights the importance of stringent quality control and regulatory oversight in pharmaceutical manufacturing. While the majority of metformin products tested met safety standards, the detection of NDMA in certain batches necessitates ongoing vigilance and corrective measures to protect patient health. Regulatory agencies and pharmaceutical companies must continue to collaborate to ensure the safety and efficacy of metformin and other essential medications.
Sources and full results
Most relevant research papers on this topic